Maunjaro's domestic release date, price, reviews, efficacy, and side effects are all covered! Compare it to Wegobi and discover helpful tips for choosing a diet injection.

1. What is Maunjaro?

Maunjaro is a GLP-1 + GIP dual agonist.

GLP-1: Maintains satiety + suppresses appetite

GIP: Promotes insulin secretion and improves metabolism

 

That is, compared to the existing Wigobi (semaglutide, GLP-1 only agent) The point is that it has better weight loss effects and blood sugar control ability!

2. Domestic release date for Maunjaro

Release Date: August 14, 2025 (Official domestic release)

Distribution start date: August 20, 2025

Prescription start date: As early as August 21, 2025

(However, it may take longer for general hospitals due to the Pharmaceutical Affairs Committee procedures.)

3. Price per horse

The current domestically released supply prices by capacity are as follows.

 

2.5mg: 278,000 won

5mg: 369,300 won

7.5mg·10mg: 521,300 won (to be released later)

 

Compared to the Wigobi, the Wigobi is a bit cheaper in the initial small capacity range, but as the capacity increases, the Maunjaro can be a more economical choice.

4. Efficacy of Maunjaro

Average weight loss of 20.2% (13.7% for stomach weight loss)

Waist circumference reduction: 18cm with Maunjaro vs. 13cm with Wegobi

Metabolic index normalization rate: Maunjaro 41% vs. Wigobi 33%

 

In a US clinical trial (SURMOUNT-5), it was reported to have shown a weight loss effect approximately 47% greater than that of Wigobi. It certainly deserves to be called the "next-generation diet injection."

5. Maunjaro Reviews & Side Effects

If you look at actual user reviews,

Initially, gastrointestinal side effects such as nausea, vomiting, diarrhea, and constipation are quite common.

They say that after about 1 to 2 months, the body adapts and the amount gradually decreases.

 

The rate of treatment discontinuation due to side effects in clinical results is

Maunjaro: 6.1%

Wegobi: 8.0%
So the mount came out a little lower.

 

However, there have been rare reports of serious side effects such as pancreatitis and gallstones, so it is best to consult a specialist before taking it.

 

6. Comparison of Wegobi vs. Maunjaro at a glance

 

Ingredients: Wegobi (GLP-1 only) vs. Maunjaro (GLP-1 + GIP dual)

Effect: Maunjaro has superior weight loss rate and speed.

Price: The initial capacity is cheaper for the Wigobi, while the high capacity is better for the Maunjaro.

Side effects: Both drugs cause gastrointestinal symptoms, but Maunjaro has relatively fewer side effects.

Data accumulation: Wegobi has more data on long-term safety.

 

In conclusion, for those looking to maximize weight loss, Maunjaro may be an attractive option. If you prioritize stability data and price, you may want to consider Wegobi first.

 

Q&A

Q1. Who is suitable for the Maunjaro?
A. It is suitable for those who did not respond well to existing diet injections and those who need to manage both diabetes and obesity.

 

Q2. Where can I get a prescription for Maunjaro?
A. It will begin at some medical institutions starting August 21, 2025, and may be slightly later for general hospitals that require hospital pharmacy committee procedures.

 

Q3. Can I transfer from Wegobi to Maunjaro?
A. It is possible, but it may vary depending on the individual's constitution and previous intake history, so it is safe to decide to change the dosage after consulting a doctor.

 

Q4. If I'm concerned about side effects, are there any alternatives?
A. Recently, health functional foods utilizing GLP-1 complex extracts have been introduced. However, they don't offer the same effectiveness as prescription drugs, so choose based on your individual needs.

 

 

Check out popular posts in real time

Who's starring in "Butterfly"? Korean-set American drama OTT release date, Hollywood action review!

How to reserve tickets for the Joseon Yokai Exhibition? Hongdae's recommended experiential horror exhibitions, early bird prices (ft. Kadeheun)

Who is Kim Jong-kook's bride-to-be? A complete summary of her age, occupation, and first meeting.